Abstract
Idiopathic pulmonary fibrosis (IPF), or usual interstitial pneumonitis (UIP) is one of the most common causes of pulmonary fibrosis. It is characterized by progressive fibrosis of both lungs. The diagnosis is usually made on the basis of high resolution CT scan of chest or open lung biopsy. Treatment for UIP has been mainly empirical. Besides lung transplant, no clear-cut medical therapy has emerged. In 2010 European union approved pirfenidone. The approval by this drug lagged in USA. On October 15th 2014, Food and Drug Administration (FDA) approved Nintedanib and Pirfenidone for patient use in United States of America. We present a brief commentary on the basic disease process and the new emerging therapies.
Keywords: IPF, nintedanib, pirfenidone, UIP.
Current Respiratory Medicine Reviews
Title:Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?
Volume: 10 Issue: 4
Author(s): Shawn Johnson and Salim Surani
Affiliation:
Keywords: IPF, nintedanib, pirfenidone, UIP.
Abstract: Idiopathic pulmonary fibrosis (IPF), or usual interstitial pneumonitis (UIP) is one of the most common causes of pulmonary fibrosis. It is characterized by progressive fibrosis of both lungs. The diagnosis is usually made on the basis of high resolution CT scan of chest or open lung biopsy. Treatment for UIP has been mainly empirical. Besides lung transplant, no clear-cut medical therapy has emerged. In 2010 European union approved pirfenidone. The approval by this drug lagged in USA. On October 15th 2014, Food and Drug Administration (FDA) approved Nintedanib and Pirfenidone for patient use in United States of America. We present a brief commentary on the basic disease process and the new emerging therapies.
Export Options
About this article
Cite this article as:
Johnson Shawn and Surani Salim, Emerging Approved Treatments for Idiopathic Pulmonary Fibrosis: Some Hope for Patients?, Current Respiratory Medicine Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/1573398X11666141208233106
DOI https://dx.doi.org/10.2174/1573398X11666141208233106 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Lipoprotein(a) Management: Pharmacological and Apheretic Treatment
Current Medicinal Chemistry Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews <i>Helicobacter Pylori</i> Interacts with Serum Vitamin D to Influence Hypertension
Current Aging Science Non-Steroidal Anti-Inflammatory Drugs Loaded Liposomes for Topical Treatment of Inflammatory and Degenerative Conditions
Current Medicinal Chemistry Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Platelet-neutrophil Interactions as a Target for Prevention and Treatment of Transfusion- related Acute Lung Injury
Current Pharmaceutical Design Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science Inherited Renal Diseases
Current Pediatric Reviews Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Potential Role of Natural Compounds Against Skin Aging
Current Medicinal Chemistry Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?
Current Drug Safety Adventure of Recombinant Human Activated Protein C in Sepsis and New Treatment Hopes on the Horizon
Recent Patents on Inflammation & Allergy Drug Discovery